Skip to content
drillr.ai
Sign up

TSHA

Taysha Gene Therapies, Inc.

NASDAQ · Healthcare · Biotechnology · US

$5.02
−2.71%
Ask drillr
0
Insider buys (3m)
1
Insider sells (3m)
-$1.2M
Net value (3m)
-23.3%
Price return (3m)
Form 4 filings
DateInsiderActivitySharesPrice
Jul 10, 2026Nagendran Sukumar · director, officer: President and Head of R&DSale200,000$6.24
Jun 2, 2026Long Alison S · directorA-Award21,335$0.00
Jun 2, 2026Long Alison S · directorA-Award42,671$5.97
Jun 2, 2026Sepp-Lorenzino Laura · directorA-Award21,335$0.00
Jun 2, 2026Sepp-Lorenzino Laura · directorA-Award42,671$5.97
Jun 2, 2026Donenberg Phillip B. · directorA-Award42,671$5.97
Jun 2, 2026Stalfort John A III · directorA-Award21,335$0.00
Jun 2, 2026Stalfort John A III · directorA-Award42,671$5.97
Jun 2, 2026Donenberg Phillip B. · directorA-Award21,335$0.00
Apr 13, 2026Nagendran Sukumar · director, officer: President and Head of R&DM-Exempt19,021$1.71
Apr 13, 2026Nagendran Sukumar · director, officer: President and Head of R&DSale200,000$4.46
Feb 6, 2026Alam Kamran · officer: CHIEF FINANCIAL OFFICERSale1,655$4.52
Jan 27, 2026Alam Kamran · officer: CHIEF FINANCIAL OFFICERSale23,849$4.61
Jan 27, 2026Nagendran Sukumar · director, officer: President and Head of R&DSale26,918$4.61
Jan 27, 2026Nolan Sean P. · director, officer: Chief Executive OfficerSale136,789$4.75
Jan 27, 2026Nagendran Sukumar · director, officer: President and Head of R&DSale89,132$4.75
Jan 27, 2026Nolan Sean P. · director, officer: Chief Executive OfficerSale41,312$4.61
Jan 27, 2026Alam Kamran · officer: CHIEF FINANCIAL OFFICERSale78,968$4.75
Jan 14, 2026Nolan Sean P. · director, officer: Chief Executive OfficerA-Award648,000$4.86
Jan 14, 2026Alam Kamran · officer: CHIEF FINANCIAL OFFICERA-Award359,000$0.00
Jan 14, 2026Alam Kamran · officer: CHIEF FINANCIAL OFFICERA-Award231,000$4.86
Jan 14, 2026Nolan Sean P. · director, officer: Chief Executive OfficerA-Award1,008,000$0.00
Jan 14, 2026Nagendran Sukumar · director, officer: President and Head of R&DA-Award427,000$0.00
Jan 14, 2026Nagendran Sukumar · director, officer: President and Head of R&DM-Exempt88,676$1.71
Jan 14, 2026Nagendran Sukumar · director, officer: President and Head of R&DM-Exempt111,324$0.70
Jan 14, 2026Nagendran Sukumar · director, officer: President and Head of R&DSale200,000$4.71
Jan 14, 2026Nagendran Sukumar · director, officer: President and Head of R&DA-Award274,000$4.86
Dec 1, 2025Nagendran Sukumar · director, officer: President and Head of R&DM-Exempt39,953$1.71
Dec 1, 2025Nagendran Sukumar · director, officer: President and Head of R&DM-Exempt70,172$0.70
Dec 1, 2025Nagendran Sukumar · director, officer: President and Head of R&DSale110,125$4.75
Institutional positioning

13F filings over the trailing two quarters

New 76Increased 168Reduced 95Sold out 23
FilerActionSharesFiled
Avoro Capital Advisors LLCIncreased23,888,888Aug 14, 2026
RA CAPITAL MANAGEMENT, L.P.Unchanged23,555,648Aug 14, 2026
RA CAPITAL MANAGEMENT, L.P.Unchanged23,555,648May 15, 2026
GOLDMAN SACHS GROUP INCIncreased22,713,118Aug 14, 2026
GOLDMAN SACHS GROUP INCReduced22,369,645May 15, 2026
AVORO CAPITAL ADVISORS LLCReduced21,700,000May 15, 2026
BlackRock, Inc.Increased20,691,927Aug 7, 2026
Vestal Point Capital, LPIncreased19,415,000Aug 14, 2026
BLACKROCK, INC.Reduced18,365,608May 13, 2026
VESTAL POINT CAPITAL, LPIncreased18,000,000May 15, 2026
MORGAN STANLEYReduced17,965,371May 15, 2026
MORGAN STANLEYReduced16,487,479Aug 13, 2026
FMR LLCIncreased14,321,255May 15, 2026
GOLDMAN SACHS GROUP INCIncreased13,692,739Mar 25, 2026
RTW INVESTMENTS, LPReduced13,680,248May 15, 2026

Insider activity from SEC Form 4; institutional positioning from 13F filings · Latest filing Jul 10, 2026